Physician profile
Ofer Feder
NPI 1801882501
$4,810.57
in general payments reported to CMS, 2019-2025
36 companies · $722 in 2025
The $722 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $217 · 2021: $863 · 2022: $851 · 2023: $1,017 · 2024: $611 · 2025: $722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,349.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,729.85 | 2019-2025 | |
| Pfizer INC. | $552.77 | 2019-2025 | |
| Celgene Corporation | $437.03 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $233.46 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156.53 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $154.38 | 2019-2025 | Entyvio |
| Conmed Corporation | $142.78 | 2024 | Conmed Generators, Conmed Biliary, Conmed Hemostasis |
| Alnylam Pharmaceuticals INC. | $140.65 | 2022-2025 | Givlaari |
| Nestle Healthcare Nutrition INC. | $113.60 | 2021-2023 | |
| Gilead Sciences, INC. | $99.52 | 2020-2024 | |
| Aimmune Therapeutics, INC. | $95.68 | 2025 | Vowst |
| Echosens North America, INC. | $89.85 | 2024 | Fibroscan |
| Ambu INC. | $84.53 | 2020 | |
| Braintree Laboratories, INC. | $78.51 | 2019-2023 | Suflave |
| Lilly USA, LLC | $71.93 | 2025 | Omvoh |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $66.10 | 2023 | Rebyota |
| Ardelyx, INC. | $54.30 | 2025 | Ibsrela |
| Medtronic, INC. | $51.14 | 2025 | Nexpowder |
| Sandoz INC. | $43.09 | 2023-2025 | Hyrimoz |
| Novo Nordisk INC | $40.80 | 2025 | Wegovy |
| Boston Scientific Corporation | $39.39 | 2024-2025 | Wallflex Duodenal |
| Intercept Pharmaceuticals, INC. | $36.86 | 2019-2025 | |
| Qol Medical, LLC | $33.23 | 2019 | |
| Ironwood Pharmaceuticals, INC | $31.36 | 2019-2022 | |
| Enterra Medical, INC. | $28.10 | 2025 | |
| Celltrion USA INC. | $27.29 | 2025 | Vegzelma |
| Cumberland Pharmaceuticals, INC. | $25.00 | 2024 | Sancuso |
| Apollo Endosurgery US INC | $24.67 | 2022 | |
| Organon LLC | $23.31 | 2023-2024 | Hadlima, Renflexis |
| Shire North American Group INC | $20.92 | 2019 | |
| Intra-Sana Laboratories | $19.49 | 2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Vivus LLC | $18.12 | 2025 | Pancreaze |
| Fresenius Kabi USA, LLC | $13.46 | 2024 | Idacio |
| Allergan, INC. | $12.29 | 2020 | |
| Olympus America INC. | $11.39 | 2019 | |
| Phathom Pharmaceuticals, INC. | $9.19 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ofer Feder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.